share_log

Y-mAbs Reports Preliminary Estimated 2024 Total Net Revenue Of $88M, Within $87M - $91M Prior Guidance Range; Est $88.221M

Benzinga ·  Jan 10 20:15

Anticipated 2025 Milestones

  • Part A data from GD2-SADA Phase 1 trial (Trial 1001) expected to be presented in the second quarter of 2025
  • GD2-SADA optimization data expected to be presented in the second quarter of 2025
  • Expect to present updates with respect to reprioritized SADA PRIT pipeline, including new high-value target indications and timelines, in the second quarter of 2025
  • Expect to dose first patient in CD38-SADA Phase 1 trial (Trial 1201) in the first quarter of 2025
  • Potential for marketing approval of DANYELZA in new ex-U.S. market in 2025
  • Plan to provide full year 2025 guidance in conjunction with full year 2024 earnings report in the first quarter of 2025
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment